Navigation Links
Boston Scientific Announces FDA Approval of New Heart Failure Lead
Date:5/16/2008

isks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corpor
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
2. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
3. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
4. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
5. Fraunhofer and Boston University Hosted Prestigious SME Tour
6. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
7. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
8. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
9. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
10. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
11. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/28/2014)... NY (PRWEB) August 28, 2014 Whitehouse ... its long term partnership with PTI Inspection Systems ... clients with state of the art leak testing method ... the art instruments currently available. As part of this ... High Voltage Leak Detection Instrument developed and ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a biopharmaceutical ... data from its ICH compliant Phase II equivalent,multi-center ... allergic,rhinitis. MRX-4 was given as an intranasal spray ... was conducted in allergic,rhinitis patients outside of the ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 13,2008, at ... and operating,performance for its first fiscal quarter ended ... product development and marketing activities., Corgenix invites ...
... ... flavor enhancer may be used in beverages, foods and oral care ... to reduce the need for sucralose, SAN DIEGO, CA AND ... a leading company,focused on using proprietary technologies to discover and develop ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5
(Date:8/27/2014)... may not be getting effective doses of the HIV ... The initial dosing studies, completed before the drug was ... a protein that is key to removing maraviroc from ... maximum levels of the protein including nearly half ... their bodies compared to those who lack the protein ...
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... Research Hospital have discovered that a certain differentiated cell ... it requires the constant expression of a gene called ... that Prox1 acts as a two-way switch whose inactivity ... called a lymphatic endothelial cell (LEC). In the absence ...
... and then presented with a chemoattractant signal like cAMP, individual ... a migrating stream. This is the first step in a ... organism. Kriebel et al. show how this streaming response is ... issue of the Journal of Cell Biology ( ...
... deformity known as pectus excavatum corrected report improved body ... published December in the journal Pediatrics . ... telephone interviews of more than 200 patients between the ... surgery. Researchers interviewed parents as well. The ...
Cached Biology News:Reprogrammable cell type depends on a single gene to keep its identity 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3
Request Info...
NATIVE RAT OSTEOCALCIN...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: